Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next? episode artwork

EPISODE · Dec 30, 2024 · 47 MIN

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?

from Connected With Latham

In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio's Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian Stephenson. Since 2015, BridgeBio, a commercial-stage biopharmaceutical, has maintained a mission to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. Latham has been involved with BridgeBio since its inception, representing BridgeBio on multiple fronts, including recently the company's US$1.25 billion cross-border capital financing, one of the largest private capital financings in life sciences in the last five years and one of the largest combined senior debt and royalty transactions in the last decade. In a wide-ranging conversation, Haim, Neil, and Brian discuss BridgeBio's novel rise from startup to unicorn, how the company's portfolio has increasingly diversified and adjusted, and why BridgeBio represents the right approach to establishing enterprise and patient value in the genetics — and broader biotech — space. They also reflect on balancing patient impact with value creation, their anticipation of faster approval timelines in a new presidential administration, and the lessons learned from the evolution of BridgeBio's legal structure, as well as which fast food is near and dear to their stomachs, and who was the biggest nerd in grad school.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Episode metadata supplied by the publisher feed · Published Dec 30, 2024

Embed this episode

Ready to play

Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?

0:00 47:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Connected With Latham?

This episode is 47 minutes long.

When was this Connected With Latham episode published?

This episode was published on December 30, 2024.

Can I download this Connected With Latham episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!